Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

PURPOSE: BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related proteins BCL-x(l) and BCL-w, potently inducing apoptosis of CLL cells in vitro. A phase I trial in patients with CLL was conducted to ev...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Roberts, Andrew W., Seymour, John F., Brown, Jennifer R., Wierda, William G., Kipps, Thomas J., Khaw, Seong Lin, Carney, Dennis A., He, Simon Z., Huang, David C.S., Xiong, Hao, Cui, Yue, Busman, Todd A., McKeegan, Evelyn M., Krivoshik, Andrew P., Enschede, Sari H., Humerickhouse, Rod
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2012
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979082/
https://ncbi.nlm.nih.gov/pubmed/22184378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.34.7898
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares